Level Four Advisory Services’s BioCryst Pharmaceuticals BCRX Stock Holding History

Level Four Advisory Services’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-39,681	Closed	-$645K	–	566
2022 Q1	$645K	Buy	+39,681	New	+$637K	0.05%	331

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Level Four Advisory Services's BCRX Position: Q2 2022 in Review

Level Four Advisory Services sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2022, closing a stake of 39,681 shares — an estimated $645K sold.

Level Four Advisory Services first reported a position in BCRX in Q1 2022 and held it in 1 quarter. The position peaked at $645K in Q1 2022. 221 funds tracked by Wall St. Rank hold BCRX as of Q2 2022.

Level Four Advisory Services reported no remaining BioCryst Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Level Four Advisory Services sold 39,681 BioCryst Pharmaceuticals shares in Q2 2022, an estimated $645K.
Level Four Advisory Services first reported a position in BioCryst Pharmaceuticals in Q1 2022 and held it in 1 quarter.
Level Four Advisory Services's BioCryst Pharmaceuticals position peaked at $645K in Q1 2022.
221 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2022.

Based on Level Four Advisory Services's 13F filing for Q2 2022, filed 8 Aug 2022.